Tianjin Yugen Medtech Development Co., Ltd. announced that it expects to receive CNY 100 million in funding from Asymchem Laboratories Co., Ltd., Haiying Chuang Investment Management Co., Ltd., Heji Enterprise Management Consulting Partnership (L.P.), Jinji Enterprise Management Consulting Partnership (L.P.), Tianjin Tianhao Management Consulting Partnership Enterprise (Limited Partnership)
July 02, 2021
Share
Tianjin Yugen Medtech Development Co., Ltd. announced a private placement of CNY 100 million on July 2, 2021. The transaction included participation from new investor Tianjin Tianhao Management Consulting Partnership Enterprise (Limited Partnership) will subscribe to registered capital of CNY 3,418,800 for CNY 20 million, returning investors Asymchem Laboratories (Tianjin) Co., Ltd. will subscribe to registered capital of CNY 4,444,400 for CNY 26 million, Tianjin Haihe Kailaiying Biopharmaceutical Industry Innovation Investment Fund (L.P.), a fund managed by Haiying Chuang (Tianjin) Investment Management Co., Ltd. will subscribe to registered capital of CNY 4,102,600 for CNY 24 million, Heji (Tianjin) Enterprise Management Consulting Partnership (L.P.) will subscribe to registered capital of CNY 1,367,500 for CNY 8 million and Jinji (Tianjin) Enterprise Management Consulting Partnership (L.P.) will subscribe to registered capital of CNY3,760,700 for CNY22 million. On post completion, Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) will acquire 29.08% stake, Tianjin Haihe Kailaiying Biopharmaceutical Industry Innovation Investment Fund (L.P.), a fund managed by Haiying Chuang (Tianjin) Investment Management Co., Ltd. will acquire 26.84% stake, Heji (Tianjin) Enterprise Management Consulting Partnership (L.P.) will acquire 8.95% stake, Jinji (Tianjin) Enterprise Management Consulting Partnership (L.P.) will acquire 24.60% stake and Tianjin Tianhao Management Consulting Partnership Enterprise (Limited Partnership) will acquire 10.53% stake in the company. . The transaction has been approved by the board of directors of the company at the 7th session of the company of the 4th directorate and at the 6th session of the company by the 4th supervisory board.
Asymchem Laboratories (Tian Jin) Co Ltd is a China-based company mainly engaged in the contract development manufacturing organization (CDMO) of drugs. The Company's main businesses are the process development, amplification and commercialization of chemical drugs. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company is also engaged in the provision of pharmaceutical formulation solutions, biosynthetic solutions and clinical solutions.